Business Context and Reporting Period
Company: Arvinas, Inc.
Filing Type: Form 8-K (Current Report)
Date: May 29, 2020
Context: The filing discloses updated clinical data from the dose escalation portion of Phase 1/2 trials for two product candidates: ARV-110 (targeting androgen receptor in prostate cancer) and ARV-471 (targeting estrogen receptor in breast cancer). The company is an emerging growth company.
Key Financial Metrics
This Form 8-K is a disclosure of clinical trial updates and does not contain financial statements. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes and Clinical Updates
ARV-110 (Prostate Cancer)
- Efficacy: Evidence of in-tumor androgen receptor (AR) reduction was observed, marking the first demonstration of successful targeted protein degradation by a PROTAC in humans.
- PSA Responses: Among 12 patients treated at 140 mg or higher with degradable AR forms, two achieved confirmed PSA responses:
- Patient 1: 74% PSA decline; no progression after 30 weeks.
- Patient 2: 97% PSA decline and 80% tumor mass reduction (RECIST response); no progression after 18 weeks.
- Safety/Toxicity: A potential drug-drug interaction was identified between ARV-110 and rosuvastatin (ROS), causing elevated liver enzymes and acute renal failure in one patient. Concomitant use of ROS was precluded; no further Grade 3/4 events related to this interaction have been reported.
- Progression: Dose escalation continues with a new cohort initiating at 420 mg in May 2020.
ARV-471 (Breast Cancer)
- Status: Dose escalation continues with no dose-limiting toxicities observed to date.
- Pharmacokinetics: Exposure levels associated with tumor growth inhibition were reached in the first 30 mg cohort.
- Efficacy: Early evidence of estrogen receptor (ER) degradation observed.
Guidance, Outlook, and Risks
- Timeline: The company plans to provide updated information on the ARV-110 Phase 1/2 trial by the end of 2020. Additional clinical data for ARV-471 is expected in the fourth quarter of 2020.
- Next Steps: The expansion portion of the Phase 1/2 trials will begin once the recommended Phase 2 dose is determined.
- Risks: Forward-looking statements are subject to risks including the ability to successfully conduct clinical trials, receive results on expected timelines, and whether cash resources will be sufficient to fund operations.
Investor Verification Checklist
- Verify the full text of the press release (Exhibit 99.1) and presentation (Exhibit 99.2) for detailed statistical data not summarized in the 8-K.
- Confirm the status of the recommended Phase 2 dose determination for ARV-110.
- Monitor future filings for updates on the drug-drug interaction management regarding rosuvastatin.
- Review the company's most recent 10-Q or 10-K for current cash runway and liquidity status, as this 8-K does not contain financial data.